New high-throughput screening assay is designed to identify inhibitors of the androgen receptor, which plays a vital role in the progression of prostate cancer.
Scientists have also identified more natural recipes for ameliorating mild to moderate lower urinary tract symptoms (LUTS) in men with enlarged prostate.
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.